Fifteen abstracts on Non-Hodgkin Lymphoma (NHL) will be presented, focusing on the use of minimal residual disease (MRD) to assess depth of response and guide therapy. In diffuse large B-cell lymphoma (DLBCL), results from a phase II Wisconsin Oncology Network study using clonoSEQ to de-escalate therapy in frail older adults will be featured (poster presentation, abstract 1964). Additional data supporting the integration of circulating tumor DNA (ctDNA) into post–CAR T surveillance will also be presented (oral presentation, abstract 941).
In mantle cell lymphoma (MCL), results from a phase II MRD-guided study in older patients demonstrate the use of clonoSEQ to guide the duration of frontline BOVen therapy (zanubrutinib, obinutuzumab, venetoclax) (oral presentation, abstract 888).
Seven abstracts on chronic lymphocytic leukemia (CLL) utilizing clonoSEQ MRD will be presented, mainly focusing on assessing treatment response and guiding treatment discontinuation. A Phase II study involving 80 previously untreated CLL patients showed that a time-limited combination of pirtobrutinib, venetoclax, and obinutuzumab (PVO) achieved deep and durable remissions based on MRD assessment at a 10-6 threshold. MRD positive status determined by clonoSEQ was used to identify patients who might benefit from continued therapy, highlighting clonoSEQ as a potential tool for guiding treatment duration in this regimen (oral presentation, abstract 680).
In acute lymphoblastic leukemia (ALL), 30 abstracts will describe the use of clonoSEQ to assess treatment response in both investigator studies and real-world data, along with analyses comparing bone marrow and peripheral blood MRD measurements.
Susan Bobulsky, chief commercial officer for MRD at Adaptive Biotechnologies, emphasized that the extensive data presented at ASH further solidifies clonoSEQ’s leadership in blood cancer MRD monitoring. She noted the clinical evidence and real-world experience reflect clear recognition of the test’s value in advancing therapeutic progress and enhancing MRD-informed patient management.
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic test for detecting and tracking MRD in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in CLL using blood or bone marrow. The test is also available as a CLIA-validated laboratory developed test for DLBCL, MCL, and other lymphoid cancers. clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL, and MCL.
The test identifies and quantifies malignant DNA sequences, detecting one cancer cell among one million healthy cells to help clinicians monitor MRD accurately over time. clonoSEQ provides standardized, sensitive results that inform treatment decisions, predict outcomes, and enable early relapse detection.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). Details on intended use in the EU are available upon request. Information on FDA-cleared uses of clonoSEQ can be found at clonoSEQ.com/technical-summary.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on leveraging the adaptive immune system to transform disease diagnosis and treatment. Their proprietary immune medicine platform decodes the genetics of the adaptive immune system to advance drug development, diagnostics, and patient care in areas including MRD and immune medicine. The company’s products and clinical pipeline target diseases such as cancer and autoimmune disorders, aiming to enable personalized immune-driven clinical solutions.
This release contains forward-looking statements based on management’s current beliefs and available information. These statements involve risks and uncertainties that may cause actual results to differ materially from expectations. Factors affecting performance are detailed in Adaptive Biotechnologies’ filings with the Securities and Exchange Commission. The company disclaims any obligation to update forward-looking statements except as required by law.
For investor inquiries, contact Karina Calzadilla, Vice President of Investor Relations, at 201-396-1687 or [email protected].
Leave a Reply